Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
Provided are methods for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-naïve Fabry patients. Certain methods comprise administering to the patient about 100 mg to about 150 mg free base equivalent of migalastat for enhancing and/or stabilizing cardiac function.
1 - 20 . (canceled)
21 . A method of increasing midwall fractional shortening (MWFS) in a patient having Fabry disease, the method comprising administering to the patient a formulation comprising an effective amount of migalastat or salt thereof every other day for increasing the patient's MWFS, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE).
22 . The method of claim 21 , wherein the patient has impaired MWFS prior to initiating administration of the migalastat or salt thereof.
23 . The method of claim 21 , wherein the migalastat or salt thereof enhances α-galactosidase A activity.
24 . The method of claim 21 , wherein the patient is administered about 123 mg FBE of the migalastat or salt thereof every other day.
25 . The method of claim 21 , wherein the patient is administered about 123 mg of migalastat free base every other day.
26 . The method of claim 21 , wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.
27 . The method of claim 21 , wherein the formulation comprises an oral dosage form.
28 . The method of claim 27 , wherein the oral dosage form comprises a tablet, a capsule or a solution.
29 . The method of claim 21 , wherein the migalastat or salt thereof is administered for at least 12 months.
30 . The method of claim 21 , wherein the migalastat or salt thereof is administered for at least 24 months.
31 . The method of claim 21 , wherein the patient is an enzyme replacement therapy (ERT)-naïve patient.
32 . The method of claim 21 , wherein the administration of migalastat or a salt thereof provides an average increase in MWFS in a group of ERT-naïve patients with impaired MWFS of at least about 1% after 24 months of administration of migalastat or a salt thereof.
33 . The method of claim 21 , wherein the patient is an ERT-experienced patient.
34 . The method of claim 21 , wherein the patient has a HEK assay amenable mutation in α-galactosidase A.
35 . The method of claim 34 , wherein the mutation is disclosed in a pharmacological reference table.
36 . The method of claim 35 , wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease.
37 . The method of claim 35 , wherein the pharmacological reference table is provided in a product label for GALAFOLD®.
38 . The method of claim 35 , wherein the pharmacological reference table is provided at a website.
39 . The method of claim 38 , wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.
40 - 74 . (canceled)